<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298554</url>
  </required_header>
  <id_info>
    <org_study_id>19-07020513</org_study_id>
    <nct_id>NCT04298554</nct_id>
  </id_info>
  <brief_title>Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region</brief_title>
  <official_title>Comparison of Cannabinoids to Placebo in Management of Arthralgia and Myofascial Pain Disorder of the Temporomandibular Region: A Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutra Pure</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the cannabinoids taken orally in the form of
      cannabidiol (CBD oil-a major non-psychoactive component of marijuana) or placebo (hemp oil)
      will provide pain relief and improved jaw function in those who suffer from either myofascial
      pain disorder and/or arthralgia of the temporomandibular region. The study hypothesis is that
      CBD oil is superior to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in baseline in pain, as measured by the Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline, 3 weeks, 7 weeks, and 11 weeks</time_frame>
    <description>Scores are measured from 1-100mm VAS. The VAS ranges from 0 to 100 with O indicating no pain and higher scores indicating a greater pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in jaw functional limitations as measured by the jaw functional limitation scale</measure>
    <time_frame>Baseline, 3 weeks, 7 weeks, and 11 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>TMJ Disorder</condition>
  <condition>Myofacial Pain</condition>
  <condition>TMD</condition>
  <arm_group>
    <arm_group_label>CBD Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBD PURE CBD OIL 20mg/1ml concentration - 1 ml (20mg) qd PO, hold under tongue for 1 minute and swallow daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (hemp oil)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CBD PURE Hemp Oil- 1 ml qd PO, hold under tongue for 1 minute and swallow daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBD Oil</intervention_name>
    <description>CBD PURE CBD OIL 20mg/1ml concentration</description>
    <arm_group_label>CBD Oil</arm_group_label>
    <other_name>Cannabinoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hemp Oil</intervention_name>
    <description>CBD PURE HEMP OIL</description>
    <arm_group_label>Placebo (hemp oil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-70 years of age

          -  Ability to give informed consent

          -  Arthralgia of the temporomandibular joint as defined according to the RDC/TMD criteria
             (see below chart)[3] and/or Myofascial pain of masticatory muscles as defined
             according to the RDC/TMD criteria (see below chart)[3]

          -  Baseline pain must be greater than 3/10 as self-reported on the VAS

        Exclusion Criteria:

          -  Allergy to study drug

          -  Traumatic injury of masticatory muscles or temporomandibular joint within last 12
             months

          -  Mandibular fracture within last 12 months

          -  Pregnancy or breast feeding

          -  Initiation of additional treatment of MPD within the past 1 months

          -  Baseline pain less than 3/10 as self-reported on the VAS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gwendolyn Reeve, DMD FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell New York Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gwendolyn Reeve, DMD FACS</last_name>
    <phone>212-746-5175</phone>
    <email>gsr9001@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gwendolyn Reeve, DMD FACS</last_name>
      <phone>212-746-5175</phone>
      <email>gsr9001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Gwendolyn Reeve, DMD FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>TMJ</keyword>
  <keyword>TMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

